Abstract | BACKGROUND: PATIENTS AND METHODS: Between November 2006 and December 2011, 46 patients with advanced gastric cancer refractory to fluoropyrimidine and platinum were treated with CM (n=22) or CA (n=24). RESULTS: Baseline characteristics of the patients were similar in the two treatment groups, with the exception of the sex ratio. The median progression-free survival was 3.9 months in the CM arm and 3.7 months in the CA arm (p=0.25), and the median overall survival was 9.6 and 8.7 months (p=0.36), respectively. The overall response rate was 18% in the CA arm and 9% in the CM arm (p=0.38). Grade 3/4 neutropenia (45% vs. 25%), anemia (36% vs. 4%), febrile neutropenia (14% vs. 8%), anorexia (14% vs. 8%) tended to be higher in the CM arm than in the CA arm. CONCLUSION: Although the efficacy of CM and CA for advanced gastric cancer refractory to fluoropyrimidine and platinum was not significantly different, CM tended to lead to greater incidence of adverse events in clinical practice.
|
Authors | Akira Ueda, Ayumu Hosokawa, Kohei Ogawa, Hiroki Yoshita, Hiroshi Mihara, Takayuki Ando, Shinya Kajiura, Haruka Fujinami, Jun Nishikawa, Masami Minemura, Mitsuhiro Terada, Takashi Kobayashi, Naoki Horikawa, Kazuhisa Yabushita, Masayuki Note, Toshiro Sugiyama |
Journal | Anticancer research
(Anticancer Res)
Vol. 33
Issue 11
Pg. 5107-11
(Nov 2013)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 24222156
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Platinum
- Mitomycin
- Irinotecan
- Fluorouracil
- Camptothecin
|
Topics |
- Adenocarcinoma
(drug therapy, mortality, pathology)
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Camptothecin
(administration & dosage, analogs & derivatives)
- Drug Resistance, Neoplasm
(drug effects)
- Female
- Fluorouracil
(administration & dosage)
- Follow-Up Studies
- Humans
- Irinotecan
- Male
- Middle Aged
- Mitomycin
(administration & dosage)
- Neoplasm Metastasis
- Neoplasm Staging
- Platinum
(administration & dosage)
- Prognosis
- Salvage Therapy
- Stomach Neoplasms
(drug therapy, mortality, pathology)
- Survival Rate
|